Nuvalent IncNUVL
Price$123.96

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$450.1MTTM through 31 Mar 2026
Free Cash Flow -$312.8MTTM through 31 Mar 2026

Margins

Current

Returns

-38.3%ROE
-33.8%ROA

Balance Sheet Health

Current Ratio16.14x
Net Debt-$1.3Bnet cash position
Cash & Equivalents$159.7M

Quality Metrics

Altman Z-Score36.42
Piotroski F-Score2 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Diluted EPS-$6.06TTM
'20'21'22'23'24'25
FY2025: $-5.85

Dividend

No dividend

Capital Allocation

R&D Spend$316.2M

Segment Performance

SegmentRevenueYoYOutlook
Oncology Therapeutics$0
View details

Transitioning to a commercial-stage biopharmaceutical company with potential launches in late 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.